Home > Publications Database > Excessive Supraventricular Ectopic Activity in Patients With Acute Ischemic Stroke Is Associated With Atrial Fibrillation Detection Within 24 Months After Stroke: A Predefined Analysis of the MonDAFIS Study. > print

001     276159
005     20250209000724.0
024 7 _ |a 10.1161/JAHA.123.034512
|2 doi
024 7 _ |a pmid:39791425
|2 pmid
024 7 _ |a altmetric:173027025
|2 altmetric
037 _ _ |a DZNE-2025-00231
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Haeusler, Karl Georg
|0 0000-0002-6389-5054
|b 0
245 _ _ |a Excessive Supraventricular Ectopic Activity in Patients With Acute Ischemic Stroke Is Associated With Atrial Fibrillation Detection Within 24 Months After Stroke: A Predefined Analysis of the MonDAFIS Study.
260 _ _ |a New York, NY
|c 2025
|b Association
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1738669617_28058
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Excessive supraventricular ectopic activity (ESVEA) is regarded as a risk marker for later atrial fibrillation (AF) detection.The investigator-initiated, prospective, open, multicenter MonDAFIS (Impact of Standardized Monitoring for Detection of Atrial Fibrillation in Ischemic Stroke) study randomized 3465 patients with acute ischemic stroke without known AF 1:1 to usual diagnostic procedures for AF detection or additive Holter monitoring in hospital for up to 7 days, analyzed in a core laboratory. Secondary study objectives include the comparison of recurrent stroke, myocardial infarction, major bleeding, and all-cause death within 24 months in patients with ESVEA (defined as ectopic supraventricular beats ≥480/day or atrial runs of 10-29 seconds or both) versus patients with newly diagnosed AF versus patients without ESVEA or AF (non-ESVEA/AF), randomized to the intervention group. Overall, 1435 (84.8%) of 1714 patients randomized to the intervention group had analyzable study ECG monitoring of at least 48 hours' duration within the first 72 hours of monitoring. ESVEA was detected in 363 (25.3%) patients, while AF was first detected in 48 (3.3%) patients. Within 24 months, AF was newly detected in 67 (18.5%) patients with ESVEA versus 60 (5.9%) patients without ESVEA/AF- (P<0.001). The composite outcome at 24 months was not different between patients with ESVEA and patients without ESVEA/AF (15.2% versus 12.6%; P=0.242). All-cause death was numerically higher in patients with ESVEA (6.6% versus 3.2%), but failed statistical significance (P=0.433) in multivariate analysis (including age, heart failure, stroke severity, and creatinine at baseline).ESVEA in the acute phase of ischemic stroke or transient ischemic attack is associated with AF detection during follow-up and therefore may be used to select patients for prolonged ECG monitoring.URL: https://www.clinicaltrials.gov; Unique identifier: NCT02204267.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ECG
|2 Other
650 _ 7 |a atrial fibrillation
|2 Other
650 _ 7 |a atrial run
|2 Other
650 _ 7 |a death
|2 Other
650 _ 7 |a stroke
|2 Other
650 _ 7 |a supraventricular ectopy
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Atrial Fibrillation: diagnosis
|2 MeSH
650 _ 2 |a Atrial Fibrillation: physiopathology
|2 MeSH
650 _ 2 |a Atrial Fibrillation: complications
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Ischemic Stroke: diagnosis
|2 MeSH
650 _ 2 |a Ischemic Stroke: mortality
|2 MeSH
650 _ 2 |a Ischemic Stroke: physiopathology
|2 MeSH
650 _ 2 |a Ischemic Stroke: etiology
|2 MeSH
650 _ 2 |a Electrocardiography, Ambulatory: methods
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Time Factors
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Atrial Premature Complexes: diagnosis
|2 MeSH
650 _ 2 |a Atrial Premature Complexes: physiopathology
|2 MeSH
650 _ 2 |a Recurrence
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
700 1 _ |a Tütüncü, Serdar
|0 0000-0002-5057-7487
|b 1
700 1 _ |a Fiessler, Cornelia
|b 2
700 1 _ |a Jawad-Ul-Qamar, Muhammad
|0 0000-0001-6336-0327
|b 3
700 1 _ |a Kunze, Claudia
|b 4
700 1 _ |a Schurig, Johannes
|0 0000-0002-8743-3743
|b 5
700 1 _ |a Dietzel, Joanna
|0 0000-0003-4739-4230
|b 6
700 1 _ |a Krämer, Michael
|0 0000-0002-0310-5903
|b 7
700 1 _ |a Petzold, Gabor C
|0 P:(DE-2719)2810273
|b 8
|u dzne
700 1 _ |a Royl, Georg
|0 0000-0002-0631-5711
|b 9
700 1 _ |a Helberg, Torsten
|b 10
700 1 _ |a Thomalla, Götz
|0 0000-0002-4785-1449
|b 11
700 1 _ |a Nabavi, Darius G
|b 12
700 1 _ |a Röther, Joachim
|0 0000-0002-8088-9991
|b 13
700 1 _ |a Laufs, Ulrich
|0 0000-0003-2620-9323
|b 14
700 1 _ |a Veltkamp, Roland
|0 0000-0002-0583-1300
|b 15
700 1 _ |a Heuschmann, Peter U
|0 0000-0002-2681-3515
|b 16
700 1 _ |a Kirchhof, Paulus
|0 0000-0002-1881-0197
|b 17
700 1 _ |a Olma, Manuel C
|0 0000-0001-8153-3025
|b 18
700 1 _ |a Endres, Matthias
|0 P:(DE-2719)2811033
|b 19
|e Last author
773 _ _ |a 10.1161/JAHA.123.034512
|g Vol. 14, no. 2, p. e034512
|0 PERI:(DE-600)2653953-6
|n 2
|p e034512
|t Journal of the American Heart Association
|v 14
|y 2025
|x 2047-9980
856 4 _ |u https://pub.dzne.de/record/276159/files/DZNE-2025-00231%20SUP.pdf
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276159/files/DZNE-2025-00231.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276159/files/DZNE-2025-00231.pdf?subformat=pdfa
856 4 _ |x pdfa
|u https://pub.dzne.de/record/276159/files/DZNE-2025-00231%20SUP.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276159
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2810273
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2811033
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b J AM HEART ASSOC : 2022
|d 2025-01-07
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-07
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-08-08T17:05:21Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-08-08T17:05:21Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2024-08-08T17:05:21Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-07
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b J AM HEART ASSOC : 2022
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 0
920 1 _ |0 I:(DE-2719)1013020
|k AG Petzold
|l Vascular Neurology
|x 1
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies (Bonn)
|l Patient Studies (Bonn)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)1013020
980 _ _ |a I:(DE-2719)1011101
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21